NTRK1 and rhabdoid tumor: Other targets that have been proposed include dual blockade of tyrosine kinase receptors; PDGF-Rα/β and FGFR-2, which have been shown to be co-activated in rhabdoid tumors and can be targeted by the tyrosine kinase inhibitor (TKI), Ponatinib [35].